Data from Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer

• DOI: 10.1158/0008-5472.c.6507711.v1
• Publication Date: 2023-04-01T01:26:47Z
• Authors: Kristin J. Lastwika; Willie Wilson; Qing Kay Li; Jeffrey Norris; Haiying Xu; Sharon R. Ghazarian; Hiroshi Kitagawa; Shigeru Kawabata; Janis M. Taube; Sheng Yao; Linda N. Liu; Joell J. Gills; Phillip A. Dennis

<div>Abstract<p>Alterations in EGFR, KRAS, and ALK are oncogenic drivers lung cancer, but how signaling influences immunity the tumor microenvironment is just beginning to be understood. Immunosuppression likely contributes because drugs that inhibit immune checkpoints like PD-1 PD-L1 have clinical benefit. Here, we show activation of AKT–mTOR pathway tightly regulates expression <i>in vitro</i> vivo</i>. Both IFNγ-mediated induction was dependent on mTOR. In human adenocarcinomas squamous cell carcinomas, membranous significantly associated with mTOR activation. These data suggest promotes escape by driving PD-L1, which confirmed syngeneic genetically engineered mouse models cancer where an inhibitor combined a antibody decreased growth, increased tumor-infiltrating T cells, regulatory cells. <i>Cancer Res; 76(2); 227–38. ©2015 AACR</i>.</p></div>